This compassionate access program is supported by Organon and is for the provision of an additional dose (free of charge) of HADLIMA® (adalimumab) 40 mg to patients who meet all eligibility criteria for the relevant indication. This additional dose is on-label as per the HADLIMA Product Information and would not otherwise be reimbursed by the PBS. The compassionate use product available in this program is provided by Organon.



This website is intended for use by Australian healthcare professionals only (registration and verification is required) and is designed to comply with Australian law and regulations only. If you are a patient seeking medical advice, please contact your healthcare professional.